OTC Drug Monograph Registration: What Manufacturers Need to Know

How the OTC Drug Monograph System Works

The OTC drug monograph system is a unique regulatory framework that allows over-the-counter drugs to be marketed without individual premarket approval, provided they comply with an applicable monograph. Each monograph is essentially a "recipe book" that specifies the acceptable active ingredients, dosages, formulations, labeling, and testing conditions for a particular therapeutic category.

The system originated in 1972 when FDA initiated the OTC Drug Review to evaluate the safety and effectiveness of all OTC drug ingredients already on the market. Over the following decades, FDA published monographs as final rules (codified in 21 CFR Parts 331–358) for categories such as antacids, sunscreens, antiperspirants, analgesics, cough/cold products, and many more.

If your OTC drug product contains only ingredients that are listed in a final monograph, at the specified concentrations, and meets all other monograph conditions (labeling, testing, packaging), then it can be marketed without an NDA or ANDA. This is why the monograph system is sometimes called the "OTC drug highway" — it provides a streamlined path to market.

However, if your product contains an active ingredient not covered by any monograph, uses a concentration outside monograph limits, or makes claims not supported by the monograph, you will need an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) before marketing.

The OTC Monograph Reform Act (MRA) of 2020

The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law on March 27, 2020, included Title III, Subtitle F — the Over-the-Counter Monograph Safety, Innovation, and Reform Act (OTC MRA). This legislation fundamentally changed how FDA updates and administers the OTC monograph system.

Before the MRA, FDA updated monographs through the formal rulemaking process (notice-and-comment rulemaking), which often took decades. Many monographs were stuck in "tentative final" status for years, leaving manufacturers and regulators in limbo about which ingredients and claims were permissible.

The MRA replaced rulemaking with an administrative order process, giving FDA the authority to issue, amend, or revoke monograph orders much faster. Key changes under the MRA include:

• Administrative orders replace rulemaking — FDA can now modify monograph conditions through orders that take effect more quickly than regulations
• User fees — the MRA authorized FDA to collect user fees from OTC monograph drug facilities to fund the monograph reform process (OTC Monograph User Facility Fee, OMUF)
• Deemed final monographs — all existing "tentative final" and "proposed" monograph conditions that were in effect before March 27, 2020 were "deemed final," resolving decades of regulatory uncertainty
• Exclusivity incentives — manufacturers can obtain limited exclusivity for conducting studies that FDA requests to support a monograph change
• Sunscreen innovation — special provisions to streamline the approval of new sunscreen ingredients

The MRA also established a formal process for manufacturers to request that FDA issue, amend, or revoke a monograph order (OMOR — OTC Monograph Order Request), similar in concept to a citizen petition but specific to the monograph system.

Registration Requirements for OTC Monograph Products

Even though OTC monograph products do not require individual premarket approval, the establishment that manufactures, repackages, relabels, or processes these products must register with FDA under 21 CFR Part 207. This is a common point of confusion — registration is about the facility, not the product approval status.

Registration requirements include:

• Initial registration — within 5 days of beginning manufacturing operations. Submit through FDA's Drug Registration and Listing System (DRLS) using SPL format.
• Annual registration renewal — between October 1 and December 31 each year. All registrations must be renewed to remain active.
• Product listing — each drug product (identified by NDC number) must be listed with FDA in SPL format. Listing must be updated when new products are marketed, products are discontinued, or labeling changes.
• OMUF user fees — facilities that manufacture OTC monograph drug products are subject to the OTC Monograph User Facility Fee, established under the MRA. For FY2026, this fee is assessed annually and must be paid to maintain active registration.

Foreign establishments have the same registration and listing obligations, with the additional requirement of designating a U.S. Agent. The U.S. Agent serves as FDA's point of contact and must be physically located in the United States.

When an NDA Is Required Instead of a Monograph

Not all OTC drug products can rely on the monograph system. You will need an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) if any of the following apply:

• Your product contains an active ingredient that is not included in any final or deemed-final monograph
• The active ingredient concentration exceeds the maximum permitted by the monograph
• Your product makes therapeutic claims not supported by the monograph (e.g., a claim of effectiveness for an indication not covered)
• The product is in a dosage form not addressed by the monograph (e.g., a transdermal patch for an ingredient only monographed for oral use)
• The ingredient has been determined by FDA to be not generally recognized as safe and effective (GRASE) for OTC use
• You are marketing a new combination of active ingredients not covered by an existing monograph

Marketing an OTC drug that does not conform to an applicable monograph and does not have an approved NDA/ANDA renders the product an unapproved new drug — a violation of the FD&C Act that can result in Warning Letters, seizures, injunctions, and Import Alerts for foreign manufacturers.

Drug Facts Labeling Requirements

OTC drug products marketed under a monograph must comply with FDA's Drug Facts labeling format, codified in 21 CFR §201.66. This standardized format was introduced in 1999 to help consumers quickly find and understand key information about OTC drugs.

The Drug Facts label must include the following sections, in this order:

1. Active ingredient(s) — the therapeutic ingredient(s) and the amount per dosage unit
2. Purpose — the pharmacological category of each active ingredient (e.g., "Pain reliever," "Antacid")
3. Use(s) — the indications for which the product is marketed, using language from the monograph
4. Warnings — safety warnings including allergy alerts, dosage warnings, and when to contact a doctor
5. Directions — specific dosing instructions, including age-based dosing
6. Other information — storage conditions, calcium/ sodium content (if applicable)
7. Inactive ingredients — listed in alphabetical order

The Drug Facts format has strict typographic requirements, including minimum font size, contrast, bold/italic formatting for section headings, and the distinctive ruled box surrounding the content. Noncompliance with Drug Facts labeling is one of the most common reasons for FDA enforcement actions against OTC drug products.

Steps to Market an OTC Monograph Drug in the U.S.

If you're a manufacturer looking to bring an OTC monograph drug product to the U.S. market, follow this sequence:

1. Verify monograph coverage — confirm your active ingredient(s), concentration, dosage form, and intended claims are covered by a final or deemed-final monograph. Check 21 CFR Parts 331–358 and FDA's OTC monograph order database.
2. Obtain a DUNS number — required for FDA registration. Get one from Dun & Bradstreet at no charge.
3. Obtain a labeler code — request from FDA during your initial establishment registration SPL submission.
4. Register your establishment — submit your establishment registration in SPL format through FDA's DRLS. Foreign facilities must designate a U.S. Agent.
5. Submit product listings — list each OTC drug product with its NDC number, labeling, and product information in SPL format.
6. Ensure Drug Facts compliance — your labeling must conform to 21 CFR §201.66 and the applicable monograph conditions.
7. Pay applicable fees — OTC monograph facility user fees (OMUF) must be paid to maintain active registration.
8. Maintain cGMP compliance — OTC drugs, like all drugs, must be manufactured in compliance with 21 CFR Parts 210 and 211.

Assurentry helps foreign drug manufacturers navigate this entire process, from U.S. Agent designation through registration and listing support. Contact us for a free compliance assessment.